Results 1 to 10 of about 54,019 (242)
Dopamine agonists in prolactinomas
Endocrinology Research and Practice, 2022 -
Annamaria Colao
doaj +2 more sources
PLoS ONE, 2019 Schizophrenia and Parkinson's disease can be controlled with dopamine antagonists and agonists. In order to improve the understanding of the reaction mechanism of these drugs, in this investigation we present a quantum chemical study of 20 antagonists ...
Ana Martínez +2 more
doaj +1 more source
Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia
Frontiers in Pharmacology, 2020 Dopamine receptors are widely distributed within the brain where they play critical modulator roles on motor functions, motivation and drive, as well as cognition.
Jean Claude Martel +1 more
doaj +1 more source
Treatment of hyperprolactinemia: a systematic review and meta-analysis
Systematic Reviews, 2012 Background Hyperprolactinemia is a common endocrine disorder that can be associated with significant morbidity. We conducted a systematic review and meta-analyses of outcomes of hyperprolactinemic patients, including microadenomas and macroadenomas, to ...
Wang Amy T +14 more
doaj +1 more source
Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma
Journal of Investigative Medicine High Impact Case Reports, 2021 Dopamine agonists are generally well tolerated and represent the first-line therapy for prolactinomas. We report a case of a 20-year-old man with a macroprolactinoma who developed recurrent priapism with cabergoline and bromocriptine.
Lakshmi P. Menon MD, Wedad Rahman MD
doaj +1 more source
Progress in the study of Dopamine Receptor Agonists for Brain Protection after Ischemic Brain Injury
Zhongguo cuzhong zazhi: Ischemic brain injury comprises 87% of all brain injuries and typically results in severe functional impairments. Dopamine, the most abundant catecholamine neurotransmitter in the brain, is intimately linked with autonomous movement, emotion, sleep ...
ZHANG Linyao1, LIU Lixu1,2
doaj +1 more source
Nature Communications, 2020 Dopamine agonists increase brain glutathione levels. Here the authors identify noncanonical signalling by Nrf2 as a potential mechanism for the neuroprotective effects of dopamine D2 receptor activation.
Yao Wei +11 more
doaj +1 more source
Endocrine Connections, 2018 The dopaminergic treatment represents the primary treatment in prolactinomas, which are the most common pituitary adenomas and account for about 40% of all pituitary tumours with an annual incidence of six to ten cases per million population.
Anastasia P Athanasoulia-Kaspar +2 more
doaj +1 more source
Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report
Frontiers in Psychiatry, 2022 Prolactinomas are the most prevalent functional pituitary adenomas. They are usually treated clinically with dopamine agonists. The most widely used and suitable drug is cabergoline (CAB), a specific D2 dopamine agonists.
Ana Carolina Correa e Castro +7 more
doaj +1 more source
TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg
Frontiers in Pharmacology, 2018 Trace-amine associated receptor 1 (TAAR1) is the best-characterized member of the family of TAARs. TAAR1 is broadly expressed in the brain, especially within the monoaminergic systems.
Jian-Feng Liu, Jian-Feng Liu, Jun-Xu Li
doaj +1 more source